GERN vs DSGN
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
GERN · Geron$0.87 ▼ 4.63%
DSGN · Design Therapeutics$9.02 ▼ 3.22%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- GERN -25.0%
- DSGN +4.4%
Head to head
| Metric | GERN | DSGN |
|---|---|---|
| Price | $0.87 | $9.02 |
| Change today | ▼ 4.63% | ▼ 3.22% |
| Market cap | $560.94M | $577.61M |
| Return, 3 months | -42.7% | -40.8% |
| Return, year to date | -34.0% | -3.8% |
| Return, 1 year | -22.3% | +8.0% |
| P/E (TTM) | – | – |
| P/B | 2.5 | 2.9 |
| P/E percentile vs own 5y | 18th | 35th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +27.4% | – |
| Net profit growth (YoY) | +107.3% | -19.4% |
| Gross margin | 91.6% | – |
| Operating margin | -7.2% | – |
| Net margin | -22.0% | – |
| Return on equity | -20.1% | -36.9% |
| Analyst target vs. price | +339.9% | +140.2% |
| Analyst buy share | 75% | 100% |
| RSI (14) | 36 | 33 |
| 30-day volatility | 94.4% | 68.5% |
| Max drawdown, 1 year | -55.4% | -43.4% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- DSGN is the largest of the group by market value.
- DSGN has returned the most over the past year.
- DSGN has been the calmest stock over the last 30 days.